Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2004, for Owens & Minor, Inc. (O&M), a leading distributor of medical and surgical supplies. The filing includes unaudited consolidated financial statements and management's discussion and analysis. Note: The input metadata referenced "ACCENDRA HEALTH INC," but the provided text is exclusively for Owens & Minor, Inc.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Revenue | $1,106,074,000 | $1,017,969,000 |
| Gross Margin | $114,060,000 (10.3%) | $106,801,000 (10.5%) |
| Operating Earnings | $27,438,000 (2.5%) | $26,576,000 (2.6%) |
| Net Income | $14,625,000 | $12,891,000 |
| Diluted EPS | $0.37 | $0.35 |
| Cash from Operations | $52,902,000 | $80,088,000 |
| Cash and Equivalents (End of Period) | $46,393,000 | $3,390,000 |
| Long-Term Debt | $211,051,000 | $209,499,000 (Dec 31, 2003) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9% year-over-year, driven by a 7% increase on a per-day basis. Growth was attributed to increased sales volume to existing customers and new core distribution business.
- Margin Compression: Gross margin percentage declined to 10.3% from 10.5% due to competitive pricing pressure, increased sales volume with larger customers, and fewer inventory buying opportunities.
- Operating Earnings: Increased 3% to $27.4 million. The increase was partially offset by lower gross margins and continued investment in strategic initiatives (OMSolutions SM and Owens & Minor University).
- Financing Costs: Total financing costs dropped significantly to $3.4 million from $5.2 million in Q1 2003, primarily due to the repurchase and conversion of mandatorily redeemable preferred securities in 2003.
- Liquidity: Cash and cash equivalents surged by $30.1 million to $46.4 million, aided by improved accounts receivable collections (DSO improved to 26.1 days).
Guidance, Outlook, and Risks
- Strategic Initiatives: OMSolutions SM expenses exceeded revenue in Q1 2004 and are expected to do so in Q2 2004. Management anticipates the business will become accretive in the second half of the year.
- Capital Expenditures: Q1 2004 capex was $3.3 million. Future spending is expected to increase due to the design and construction of a new corporate headquarters, while IT spending is expected to remain lower than 2003 levels.
- Credit Facility: On May 4, 2004, the company amended its revolving credit facility, increasing the limit to $250 million and extending the expiration to May 2009. This allows for the termination of its off-balance sheet receivables financing facility.
- Risks: Key risks include competitive pricing pressure, dependence on large customers, changes in manufacturer preferences (direct sales vs. wholesale), and the ability to manage operating expenses while investing in growth.
- Acquisition: In March 2004, O&M acquired 5nQ for $2.5 million in cash plus contingent payments to enhance clinical inventory management solutions.
Investor Verification Checklist
- OMSolutions SM Profitability: Verify the timeline for OMSolutions SM to become accretive, as it currently operates at a loss.
- Gross Margin Trends: Monitor if competitive pricing pressures continue to compress gross margins below the 10.3% level.
- Customer Concentration: Assess the risk associated with the loss of any single large customer, as noted in the risk factors.
- Capital Allocation: Track the impact of the new $250 million credit facility and the termination of the receivables financing facility on future liquidity and interest costs.
- Acquisition Integration: Review the integration progress and revenue contribution of the 5nQ acquisition in subsequent quarters.